Types of Registered Studies
ClinicalTrials.gov
This table shows the number and types of studies that are registered and for which results are available on ClinicalTrials.gov.
* A study may include more than one type of intervention (that is, a single study may be counted more than once). Because of this, the sum of counts by type of intervention do not equal the total number of interventional studies.
** A total of 539 applicable device clinical trials were submitted as "delayed posting" under the Food and Drug Administration Amendments Act of 2007 (FDAAA). That is, the Responsible Party has indicated that such a trial includes a device not previously approved or cleared by the U.S. FDA for any use. These are not included in the count of trials with at least one device.
*** Results are only required to be submitted for certain studies. For example, results submission is generally not required for observational studies; trials completed before 2008; and trials that include drugs, biologics, or devices not previously approved by the U.S. FDA for any use.
N/A = not applicable
See locations of the recruiting studies here, locations of registered studies here, and numbers of registered studies over time here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
